SKLB-03220 is an orally bioavailable covalent inhibitor targeting the histone methyltransferase EZH2, an established oncology drug target involved in epigenetic regulation. SKLB-03220 is structurally based on the clinically approved EZH2 inhibitor tazemetostat and demonstrates the ability to abolish epigenetic H3K27me3 marks, thereby altering chromatin state and transcriptional activity. SKLB-03220 represents a potent small-molecule tool for cancer epigenetics research.
Citations
No citations are currently available for this product. Below are selected publications citing GlpBio products.Description
Product Documents
Purity:>97.00%Appearance:A solid
Chemical Properties
CAS No.
2852050-29-2
Synonyms
Sklb-03220; SKLB03220
SMILES
O=C(C=C)NC1=CC=C(C(=C1)C=2C=C(C(=O)NCC=3C(=O)NC(=CC3C)C)C(=C(C2)N(CC)C4CCOCC4)C)C
Molecular Formula
C33H40N4O4
Molecular Weight
556.71
Storage
-20°C
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.
CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility
g/mol
Reviews
Review for SKLB-03220
Rating: 5
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%
















